The utility of inhibitory quotients in determining the relative potency of protease inhibitors
- 1 March 2002
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 16 (5) , 799-800
- https://doi.org/10.1097/00002030-200203290-00020
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- Drug Resistance and Predicted Virologic Responses to Human Immunodeficiency Virus Type 1 Protease Inhibitor TherapyThe Journal of Infectious Diseases, 2000
- Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt StudyAIDS, 2000
- Pharmacodynamics of Human Immunodeficiency Virus Type 1 Protease InhibitorsClinical Infectious Diseases, 2000
- In Vitro Effect of α1‐Acid Glycoprotein on the Anti‐Human Immunodeficiency Virus (HIV) Activity of the Protease Inhibitor CGP 61755: A Comparative Study with Other Relevant HIV Protease InhibitorsThe Journal of Infectious Diseases, 1997